April 1, 2020 Mind Medicine Inc., a New York-based psychedelic drug development company, that counts Shark Tank star Kevin O’Leary and Toms Shoes founder Blake Mycoskie as investors, has acquired the exclusive rights to eight clinical trials
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NEO: MMED) (OTC: MMEDF) has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s UHB.
Mind Medicine (MindMed) Inc. (NEO: MMED; OTCQB: MMEDF) (the "Company" or "MindMed"), the leading psychedelic pharmaceutical company, is pleased to announce that the Company has graduated from the OTC Pink Open Market to the OTCQB Venture Market ("OTCQB").
Eight Capital's Ammar Shah mainly follows biotech and healthcare companies and is now the first analyst at an investment bank to cover the psychedelics industry.
Neuro-pharmaceutical and psychedelics research company Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) announced Wednesday the inclusion of the psychoactive compound MDMA to its R&D pipeline. The move comes as part of the company’s exclusive collaboration agreement.
Mind Medicine Inc. can lay claim to the most important one thus far. The developer of psychedelic-inspired medicines with two primary pipeline compounds just announced that one of them is being prepared for Phase 2 study.
New York, NY -- June 26, 2020-- MindMed, the leading neuro-pharmaceutical company for psychedelic inspired medicines is rapidly advancing its drug development pipeline and R&D activities since its listing on March 3, 2020.
Basel, Switzerland June 24, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc., the leading neuro-pharmaceutical company for psychedelic inspired medicines, is developing technologies and analytics that seek to personalize psychedelic therap
Basel, Switzerland June 18, 2020 // Phase 1 Trial to experiment with dosing methods to better understand how humans react to DMT, setting stage for future potential Phase 2a proof of concept trials
Basel, Switzerland, June 8, 2020 /PRNewswire/ Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB:MMEDF), is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel’s Liechti Lab.
New York, NY, June 4, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, has officially launched Project Lucy, a commercial drug development program for the treat